The amyloid precursor protein derivative, APP96-110, is efficacious following intravenous administration after traumatic brain injury.
Following traumatic brain injury (TBI) neurological damage is ongoing through a complex cascade of primary and secondary injury events in the ensuing minutes, days and weeks. The delayed nature of secondary injury provides a valuable window of opportunity to limit the consequences with a timely trea...
Main Authors: | Stephanie L Plummer, Frances Corrigan, Emma Thornton, Joshua A Woenig, Robert Vink, Roberto Cappai, Corinna Van Den Heuvel |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5761886?pdf=render |
Similar Items
-
Assessment of R18, COG1410, and APP96-110 in excitotoxicity and traumatic brain injury
by: Chiu Li Shan, et al.
Published: (2017-11-01) -
Amyloid Precursor Protein (APP) and GABAergic Neurotransmission
by: Bor Luen Tang
Published: (2019-06-01) -
β-Amyloid precursor protein (APP) and the human diseases
by: Khue Vu Nguyen
Published: (2019-10-01) -
Analysis of the overall structure of the multi-domain amyloid precursor protein (APP).
by: Ina Coburger, et al.
Published: (2013-01-01) -
Molecular Characteristics of Amyloid Precursor Protein (APP) and Its Effects in Cancer
by: Han Na Lee, et al.
Published: (2021-05-01)